Page last updated: 2024-08-16

temozolomide and melphalan

temozolomide has been researched along with melphalan in 15 studies

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (26.67)29.6817
2010's11 (73.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Garelnabi, EA; Hartley, JA; Karodia, N; Kiakos, K; Li, L; Phillips, RM; Pletsas, D; Wheelhouse, RT1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Friedman, HS; Grubbs, E; Ko, SH; Pruitt, SK; Tyler, DS; Ueno, T1
Ali-Osman, F; Augustine, CK; Friedman, HS; Pruitt, SK; Selim, MA; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Augustine, CK; Febbo, P; Gupta, M; Pendergast, AM; Peters, WP; Selim, MA; Tyler, DS; Yoshimoto, Y; Zipfel, PA1
Delashaw, JB; Doolittle, ND; Gahramanov, S; Guillaume, DJ; Hedrick, NA; Neuwelt, EA1
Ali-Osman, F; Augustine, CK; Friedman, HS; Jung, SH; Olson, JA; Sohn, I; Tyler, DS; Yoo, JS; Yoshimoto, Y1
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA1
Augustine, CK; Osmond, GW; Padussis, J; Tyler, DS; Zipfel, PA1
Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E1
Augustine, CK; Beasley, GM; Davies, MA; Deng, W; Dewhirst, MW; Fontanella, A; Lidsky, ME; Padussis, JC; Tokuhisa, Y; Toshimitsu, H; Turley, RS; Tyler, DS1

Reviews

1 review(s) available for temozolomide and melphalan

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

1 trial(s) available for temozolomide and melphalan

ArticleYear
Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
    Neurosurgery, 2010, Volume: 66, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Cross-Linking Reagents; Dacarbazine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Lomustine; Male; Melphalan; Middle Aged; Oligodendroglioma; Osmotic Pressure; Procarbazine; Temozolomide; Vincristine; Young Adult

2010

Other Studies

13 other study(ies) available for temozolomide and melphalan

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.
    ACS medicinal chemistry letters, 2012, Dec-13, Volume: 3, Issue:12

    Topics:

2012
Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma.
    American journal of surgery, 2004, Volume: 188, Issue:5

    Topics: Analysis of Variance; Animals; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Disease Models, Animal; Dose-Response Relationship, Drug; Extremities; Female; Infusions, Parenteral; Melanoma; Melphalan; Probability; Random Allocation; Rats; Rats, Nude; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Skin Neoplasms; Survival Rate; Temozolomide; Transplantation, Heterologous; Treatment Outcome

2004
Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents.
    Molecular cancer therapeutics, 2007, Volume: 6, Issue:5

    Topics: Animals; Antineoplastic Agents; Base Pair Mismatch; Cell Line, Tumor; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Infusions, Intravenous; Melanoma; Melphalan; Neoplasm Transplantation; Rats; Rats, Nude; Skin Neoplasms; Temozolomide

2007
Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment.
    Cancer research, 2008, May-15, Volume: 68, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Cadherins; Dacarbazine; DNA Adducts; Humans; Immunotherapy; Melanoma; Melphalan; Models, Biological; Neoplasm Transplantation; Phenotype; Rats; Rats, Nude; Temozolomide

2008
Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:4

    Topics: Aged; Aged, 80 and over; Cell Line, Tumor; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Male; Melanoma; Melphalan; Middle Aged; Neoplasm Metastasis; Regression Analysis; Signal Transduction; Temozolomide; Transcription, Genetic

2010
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:7

    Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays

2010
Enhancing melanoma treatment with resveratrol.
    The Journal of surgical research, 2012, Volume: 172, Issue:1

    Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Disease Models, Animal; Drug Therapy, Combination; Humans; In Vitro Techniques; Melanoma; Melphalan; Mice; Mice, Nude; Mice, SCID; Resveratrol; Skin Neoplasms; Stilbenes; Temozolomide; Treatment Outcome; Xenograft Model Antitumor Assays

2012
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2013, Volume: 29, Issue:7

    Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult

2013
Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma.
    Annals of surgery, 2015, Volume: 261, Issue:2

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cadherins; Capillary Permeability; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Dacarbazine; Melanoma; Melphalan; Neoplasm Transplantation; Oligopeptides; Peptides, Cyclic; Phosphatidylinositol 3-Kinases; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Rats; Rats, Nude; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Skin Neoplasms; Temozolomide

2015